Paris Cedex 13

• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi … Ended recruitment
  2022-502099-22-01 5 2024-04-29 HIV-1 Infection
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended recruitment
  2023-503235-18-00 4 2024-01-31 previously untreated WM
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended recruitment
  2023-503655-10-00 5 2023-11-20 Systemic Lupus Erythematosus (SLE).
• A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt … Ended recruitment
  2023-504628-24-00 4 2023-10-31 Huntington's Disease
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants with Systemic Lupus Er … Ended recruitment
  2022-502632-39-00 1 2023-10-11 Systemic Lupus Erythematosus (SLE)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Ended recruitment
  2022-500929-33-01 10 2023-05-17 Human Immunodeficiency Virus (HIV-1) infection
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Ended recruitment
  2024-511594-30-00 5 2023-02-23 Relapsed/Refractory Follicular Lymphoma
• Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Ended recruitment
  2024-514004-14-00 3 2023-02-23 Alzheimer’s Disease
• Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular … Ended recruitment
  2022-500903-38-00 3 2023-02-09 unresectable hepatocellular carcinoma
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended recruitment
  2022-500090-13-00 4 2022-12-29 Becker Muscular Dystrophy (BMD)
• Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 Ended recruitment
  2024-514381-39-00 5 2022-12-08 Gaucher's disease type III
• SIRIUS Sarcoidosis with moderate to severe facial skin involvement: an open multicenter study of the efficacy and safety of oral sirolimus Ended recruitment
  2024-514609-76-00 4 2022-11-23 Adult patients (men and women) (≥ 18 years of age) with cutaneous sarc
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis
• Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended recruitment
  2023-505302-42-00 4 2022-09-05 BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

Showing 193–216 of 312 trials